About Jürgen
Dr. Jürgen Meier studied biology and biochemistry at the universities of Freiburg im Breisgau, Sussex (England) and Dundee (Scotland). After completion of his Ph.D. at the European Molecular Biology Laboratory (EMBL) in Heidelberg, he worked for several years at the Centre de Recherche en Neuroscience of McGill University in Montréal, Canada. He joined VOSSIUS & PARTNER in 1998 and became European Patent Attorney in 2001. He is also admitted to practice as German Patent Attorney (Patentanwalt) and European Trademark Attorney and is a partner of VOSSIUS & PARTNER since 2004.Dr. Meier specializes in prosecution proceedings, oppositions, revocation proceedings as well as infringement proceedings relating to biotechnology as well as in pharmaceuticals. He has extensive experience, inter alia, in the prosecution and litigation of antibody technologies, including important drugs like blinatumomab, trastuzumab or rituximab, in the pharmaceutical area, in particular the neurological and metabolic field, including drugs in Alzheimer or in diabetes intervention, in small molecule drugs, like bisphosphonates. He has also experience in the prosecution and litigation of cases relating to fermentation technologies and microbiology, including amino acid production, alcohol fermentation and brewing technologies.Further exemplary post and present cases relate to stem cell technologies and their uses, RNA technologies, including miRNA, siRNA diagnostics and therapeutics, SNP diagnostics and biomarkers, microbiological test assays and antigen diagnostics, including M. tuberculosis, Anthrax, HPV, HCV and HIV tests, biomarkers for personalized medicine and companion diagnostics, treatment and dosage regimens, and transgenics and research tools. Also novel sequencing and gene modification technologies are comprised in his portfolio. Novel technologies handled by Dr. Meier also comprise biophysics, laser- and thermophoresis technologies. Furthermore, he advises national and international clients on employee’s remunerations and employee’s inventions and in portfolio management.Dr. Meier is the Chairman of the AIPPI Biotech Committee. Furthermore, he gives presentations and lectures on patentability issues of biotechnology, biocomputing inventions as well as formal and legal aspects of patent law. Dr. Meier has published several articles on IP matters and is a co-author of the book “From Clones to Claims” on the European Patent Office's jurisdiction in the field of biotechnology in comparison to the US and Japanese practice , 6th edition (December 2015) and he also teaches in the "D-course (legal course)" at CEIPI of the Université de Strasbourg, France, at the University of Würzburg, Germany, the Zeppelin University, Friedrichshafen, Germany as well as at the Management Center Innsbruck (MCI), in Austria.Memberships: Patentanwaltskammer, epi, AIPPI (European Member of Biotech working group), VPPLanguages: English, German, French
Dr. Jürgen Meier studied biology and biochemistry at the universities of Freiburg im Breisgau, Sussex (England) and Dundee (Scotland). After completion of his Ph.D. at the European Molecular Biology Laboratory (EMBL) in Heidelberg, he worked for several years at the Centre de Recherche en Neuroscience of McGill University in Montréal, Canada. He joined VOSSIUS & PARTNER in 1998 and became European Patent Attorney in 2001. He is also admitted to practice as German Patent Attorney (Patentanwalt) and European Trademark Attorney and is a partner of VOSSIUS & PARTNER since 2004.Dr. Meier specializes in prosecution proceedings, oppositions, revocation proceedings as well as infringement proceedings relating to biotechnology as well as in pharmaceuticals. He has extensive experience, inter alia, in the prosecution and litigation of antibody technologies, including important drugs like blinatumomab, trastuzumab or rituximab, in the pharmaceutical area, in particular the neurological and metabolic field, including drugs in Alzheimer or in diabetes intervention, in small molecule drugs, like bisphosphonates. He has also experience in the prosecution and litigation of cases relating to fermentation technologies and microbiology, including amino acid production, alcohol fermentation and brewing technologies.Further exemplary post and present cases relate to stem cell technologies and their uses, RNA technologies, including miRNA, siRNA diagnostics and therapeutics, SNP diagnostics and biomarkers, microbiological test assays and antigen diagnostics, including M. tuberculosis, Anthrax, HPV, HCV and HIV tests, biomarkers for personalized medicine and companion diagnostics, treatment and dosage regimens, and transgenics and research tools. Also novel sequencing and gene modification technologies are comprised in his portfolio. Novel technologies handled by Dr. Meier also comprise biophysics, laser- and thermophoresis technologies. Furthermore, he advises national and international clients on employee’s remunerations and employee’s inventions and in portfolio management.Dr. Meier is the Chairman of the AIPPI Biotech Committee. Furthermore, he gives presentations and lectures on patentability issues of biotechnology, biocomputing inventions as well as formal and legal aspects of patent law. Dr. Meier has published several articles on IP matters and is a co-author of the book “From Clones to Claims” on the European Patent Office's jurisdiction in the field of biotechnology in comparison to the US and Japanese practice , 6th edition (December 2015) and he also teaches in the "D-course (legal course)" at CEIPI of the Université de Strasbourg, France, at the University of Würzburg, Germany, the Zeppelin University, Friedrichshafen, Germany as well as at the Management Center Innsbruck (MCI), in Austria.Memberships: Patentanwaltskammer, epi, AIPPI (European Member of Biotech working group), VPPLanguages: English, German, French
Dr. Jürgen Meier studied biology and biochemistry at the universities of Freiburg im Breisgau, Sussex (England) and Dundee (Scotland). After completion of his Ph.D. at the European Molecular Biology Laboratory (EMBL) in Heidelberg, he worked for several years at the Centre de Recherche en Neuroscience of McGill University in Montréal, Canada. He joined VOSSIUS & PARTNER in 1998 and became European Patent Attorney in 2001. He is also admitted to practice as German Patent Attorney (Patentanwalt) and European Trademark Attorney and is a partner of VOSSIUS & PARTNER since 2004.
Dr. Meier specializes in prosecution proceedings, oppositions, revocation proceedings as well as infringement proceedings relating to biotechnology as well as in pharmaceuticals. He has extensive experience, inter alia, in the prosecution and litigation of antibody technologies, including important drugs like blinatumomab, trastuzumab or rituximab, in the pharmaceutical area, in particular the neurological and metabolic field, including drugs in Alzheimer or in diabetes intervention, in small molecule drugs, like bisphosphonates. He has also experience in the prosecution and litigation of cases relating to fermentation technologies and microbiology, including amino acid production, alcohol fermentation and brewing technologies.
Further exemplary post and present cases relate to stem cell technologies and their uses, RNA technologies, including miRNA, siRNA diagnostics and therapeutics, SNP diagnostics and biomarkers, microbiological test assays and antigen diagnostics, including M. tuberculosis, Anthrax, HPV, HCV and HIV tests, biomarkers for personalized medicine and companion diagnostics, treatment and dosage regimens, and transgenics and research tools. Also novel sequencing and gene modification technologies are comprised in his portfolio. Novel technologies handled by Dr. Meier also comprise biophysics, laser- and thermophoresis technologies. Furthermore, he advises national and international clients on employee’s remunerations and employee’s inventions and in portfolio management.
Dr. Meier is the Chairman of the AIPPI Biotech Committee. Furthermore, he gives presentations and lectures on patentability issues of biotechnology, biocomputing inventions as well as formal and legal aspects of patent law. Dr. Meier has published several articles on IP matters and is a co-author of the book “From Clones to Claims” on the European Patent Office's jurisdiction in the field of biotechnology in comparison to the US and Japanese practice , 6th edition (December 2015) and he also teaches in the "D-course (legal course)" at CEIPI of the Université de Strasbourg, France, at the University of Würzburg, Germany, the Zeppelin University, Friedrichshafen, Germany as well as at the Management Center Innsbruck (MCI), in Austria.
Memberships: Patentanwaltskammer, epi, AIPPI (European Member of Biotech working group), VPP
Languages: English, German, French
